Comparison · NCT01557322-455429be
Etanercept vs nbDMARDs: Number of Participants With Chest X-Ray Prior to New Therapy
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Etanercept vs nbDMARDs: Number of Participants With Chest X-Ray Prior to New Therapy. Trial comparisons, record NCT01557322-455429be. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01557322-455429be
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.943 | 0.901 | 0.968 | wilson | |
| Risk in group 2 | 0.515 | 0.489 | 0.541 | wilson | |
| Risk difference, group 1 minus group 2 | 0.428 | 0.379 | 0.464 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.83 | 1.72 | 1.95 | log | |
| Odds ratio, group 1 over group 2 | 15.7 | 8.45 | 29.1 | log | |
| Number needed to treat, for one more participant with the outcome on Etanercept than on nbDMARDs | 2.33 | 2.15 | 2.64 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Etanercept | Participants with moderate rheumatoid arthritis (RA), defined as disease activity score based on 28-joints count (DAS28) more than (\>) 3.2 to less than or equal to (\<=) 5.1, who received etanercept (ETN, as their first biological drug) in doses as per approved product label or summary of product characteristics (SmPC), were followed retrospectively using the data in British Society for Rheumatology Biologics Register (BSRBR) for 5 years. The doses had been adjusted according to medical and therapeutic necessity. | 183 | 194 | OG000 |
| Group 2 | nbDMARDs | Biological naïve participants with moderate RA, defined as DAS28 \>3.2 to \<=5.1, who received non-biologic disease modifying anti-rheumatic drugs (nbDMARDs) in doses as per approved product label or SmPC, were followed retrospectively using the data in BSRBR for 5 years. The doses had been adjusted according to medical and therapeutic necessity. | 742 | 1,441 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With Chest X-Ray Prior to New Therapy
- Description
- Time frame
- Baseline
- Population
- Analysis population included all enrolled participants with moderate RA at baseline. Here N (number of participants analyzed) signifies participants who were evaluable for this measure.
Source ClinicalTrials.gov
Trial
- Title
- Characterize Patients With Moderately Active Rheumatoid Arthritis (RA)
- NCT number
- NCT01557322
- Phases
- Conditions
- Rheumatoid Arthritis
- Interventions
- etanercept, methotrexate (MTX)
- Lead sponsor
- Pfizer
- Results first posted
- 2013-10-31
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01557322?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01557322-455429be